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Mucosal healing (MH) has been considered as the target in 
the treatment of inflammatory bowel disease (IBD) based on the 
observation that MH is associated with improved clinical out-
comes reducing the risk of surgery, hospitalization, and steroid 
dependency.1,2 However, endoscopic assessment, the gold stan-
dard for evaluating MH has several limitations in its clinical use 
because of its inconvenience, invasiveness, and high-cost, while 
symptom-based disease activity score has a quite discordance 
with MH.3 Thus, need for reliable, noninvasive, surrogate mark-
ers precisely reflecting the mucosal status has fuelled interests 
in the use of fecal immunochemical test (FIT) and fecal calpro-
tectin (Fcal) measurement. Although several IBD clinicians have 
used these markers as assistant tools for diagnosis, monitoring, 
and decision making for further invasive tests for years, there 
still remain controversies regarding “how to use fecal markers” 
in routine clinical practice.
In this issue of Gut and Liver, the article entitled “Fecal im-
munochemical test and fecal calprotectin results show different 
profiles in disease monitoring for ulcerative colitis”4 sought to 
determine the best choice of fecal markers in real clinical prac-
tice by evaluating changes in the values of each marker based 
on the findings of consecutive colonoscopies in patients with 
ulcerative colitis (UC). A total of 110 colonoscopy intervals from 
84 patients were identified and the data of fecal samples which 
were collected within 2 days before colonoscopy were evaluat-
ed. This study adopted cutoff values of FIT and Fcal as 100 ng/
mL, and 180 μg/g, respectively, and defined MH as Mayo endo-
scopic subscore of 0 throughout the entire colon. Interestingly, 
changes of fecal marker levels were found to have different pat-
terns according to the presence or absence of mucosal inflam-
mation in the precedent colonoscopy. FIT had an advantage in 
predicting the results of subsequent colonoscopic examinations 
in patients with MH and a negative FIT result at the precedent 
examination showed 93% of the overall accuracy compared 
with Fcal showing 79% of accuracy. On the other hand, Fcal 
measurement was superior in terms of reflecting the change 
in endoscopic activity than FIT (r=0.59, p<0.0001 vs r=0.30, 
p=0.054) in patients with a persistent high endoscopic activity. 
In addition, FIT was useful in predicting the achievement of MH 
after therapy in patients with active endoscopic inflammation at 
the precedent colonoscopy. The ratios of negative conversion of 
Fcal and FIT in these patients were 92% and 62%, respectively. 
Fecal markers have been shown to be associated with en-
doscopic disease activity, treatment response, and prediction 
for relapse. Ma et al.5 reported similar performance of FIT and 
Fcal in identifying MH in IBD patients by showing that posi-
tive predictive value (PPV) for FIT <100 ng/mL and Fcal ≤250 
μg/g were 0.78 and 0.77, respectively, but better performance 
were observed in patients with UC, particularly for FIT (area 
under the curve, 0.88 vs 0.69, p=0.05). Ryu et al.6 reported a 
positively correlation of FIT with endoscopic activity (r=0.626, 
p<0.01) and clinical activity (r=0.496, p<0.01) in patients with 
UC. Furthermore, Mooiweer et al.7 confirmed the added value 
of Fcal over MH for predicting clinical relapse and Molander et 
al.8 found a precedent increase of Fcal 6 months before clinical 
relapse in patients who discontinued anti-tumor necrosis factor 
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therapy after achieving deep remission.
In accordance with previous studies, this study4 enlarged our 
knowledge about the appropriate choice of fecal markers for 
disease monitoring at specific clinical situations of UC, and con-
firmed different values of the two markers, namely FIT as a sur-
rogate measure of bleeding from mucosal ulceration, and Fcal 
as a surrogate measure of mucosal inflammation per se.5 Based 
on these results, the authors proposed an algorithm for using 
fecal markers in specific situations. Fcal was recommended for 
the monitoring of treatment efficacy after induction therapy. On 
the other hand, FIT was recommended to monitor endoscopic 
disease activity after symptom improvement following induc-
tion therapy, and repetitively after achieving MH confirmed by 
colonoscopy due to its higher PPV for MH and low cost. A posi-
tive conversion of FIT during monitoring of stable patients aids 
in deciding further colonoscopy or additional treatment.
However, there are several limitations in using fecal markers 
in real practice. One of the major concerns regarding Fcal is its 
large variations in day-to-day, by time of day, and within the 
same bowel movement. Moreover, the ideal cutoff value has not 
yet been determined9 and discrepancies between different Fcal 
kits are another problems.10 Finally, high false positive rates of 
FIT require caution in the interpretation of results. Examinations 
of multiple samples in a serial manner are thought to reduce 
possible errors and could be more beneficial for monitoring dis-
ease activity.6 
Now, it is clear that repeated measurements of FIT and Fcal 
are well correlated with endoscopic activity in UC, and they are 
able to predict the changes of mucosa in disease course. There-
fore, this study is meaningful in terms of suggesting typical fe-
cal markers in specific situations in real clinical practice. Further 
studies are required to demonstrate whether modifications in 
medical treatments according to the results of fecal markers ul-
timately could alter the long-term disease outcomes.
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